Therapeutics News

Manitex Capital has announced that its 40% owned subsidiary, Valeo Pharma, completed the sale of its dermatology portfolio and several specialty products to Valeant Canada.

Itolizumab, a novel humanized monoclonal antibody to CD6, was found to be an effective, well-tolerated treatment for moderate-to-severe psoriasis, according to study data.

In a publication review of 32 randomized trials, researchers found that although antibiotics may have a therapeutic advantage over oral contraceptives at 3 months, by 6 months, oral contraceptives offered reductions in overall acne lesions similar to antibiotics.

A novel irritation-control retinol formulation was shown to minimize the irritation typically experienced with the use of topical tretinoin and free retinol, according to study results presented at the American Academy of Dermatology Summer Meeting.

Cubist Pharmaceuticals voluntarily recalled nine lots of daptomycin for injection because of foreign particulate matter found in reconstituted vials, according to a press release from the manufacturer.

A five-product topical regimen may provide patients with facial photodamage and hyperpigmentation with an effective, comprehensive treatment, according to study results presented at the American Academy of Dermatology Summer Meeting.

Wet wrap therapy was beneficial as an acute intervention for children with moderate-to-severe atopic dermatitis in whom other therapies have failed, according to researchers.

In a historical, prospective study, researchers found a significant risk of opportunistic infections during the first year after pemphigus diagnosis, more so in older patients, and possibly also in diabetic patients.

Limb-salvage procedures in patients with multiple limb injuries had similar outcomes compared with single-limb-injured patients despite a significantly higher injury severity score, according to study results.

Treatment of toxic epidermal necrolysis with one dose of etanercept helped patients reach complete reepithelialization, indicating that targeting tumor necrosis factor-alpha may be an effective control for the syndrome.